Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
L Gibson, D Lawrence, C Dawson… - Cochrane Database of …, 2009 - cochranelibrary.com
L Gibson, D Lawrence, C Dawson, J Bliss
Cochrane Database of Systematic Reviews, 2009•cochranelibrary.comBackground Endocrine therapy removes the influence of oestrogen on breast cancer cells
and so hormonal treatments such as tamoxifen, megestrol acetate and
medroxyprogesterone acetate have been in use for many years for advanced breast cancer.
Aromatase inhibitors (AIs) inhibit oestrogen synthesis in the peripheral tissues and have a
similar tumour‐regressing effect to other endocrine treatments. Aminoglutethimide was the
first AI in clinical use and now the third generation AIs, anastrozole, exemestane and …
and so hormonal treatments such as tamoxifen, megestrol acetate and
medroxyprogesterone acetate have been in use for many years for advanced breast cancer.
Aromatase inhibitors (AIs) inhibit oestrogen synthesis in the peripheral tissues and have a
similar tumour‐regressing effect to other endocrine treatments. Aminoglutethimide was the
first AI in clinical use and now the third generation AIs, anastrozole, exemestane and …
Background
Endocrine therapy removes the influence of oestrogen on breast cancer cells and so hormonal treatments such as tamoxifen, megestrol acetate and medroxyprogesterone acetate have been in use for many years for advanced breast cancer. Aromatase inhibitors (AIs) inhibit oestrogen synthesis in the peripheral tissues and have a similar tumour‐regressing effect to other endocrine treatments. Aminoglutethimide was the first AI in clinical use and now the third generation AIs, anastrozole, exemestane and letrozole, are in current use. Randomised trial evidence on response rates and side effects of these drugs is still limited.
Objectives
To compare AIs to other endocrine therapy in the treatment of advanced breast cancer in postmenopausal women.
cochranelibrary.com